olmesartan medoxomil has been researched along with Diabetic Glomerulosclerosis in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y | 1 |
| Cui, TX; Ding, A; Li, ZL; Yang, H; Zhang, H; Zhang, HT; Zhu, WP; Zhu, Y | 1 |
| Chatzikyrkou, C; Haller, H; Menne, J; Ritz, E; Ruilope, LM; Viberti, G | 1 |
| Amano, S; Inagaki, Y; Koga, K; Makita, Z; Okamoto, T; Saga, T; Takeuchi, M; Yamagishi, S; Yoshizuka, M | 1 |
| Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H | 1 |
| Ishikawa, N; Kurokawa, K; Miyata, T | 1 |
| Abe, Y; Kimura, S; Kiyomoto, H; Kobori, H; Kohno, M; Miyata, K; Miyatake, A; Nagai, Y; Nishiyama, A; Ozawa, Y; Shokoji, T; Yao, L; Yukimura, T | 1 |
| Fukushima, Y; Kato, M; Koike, H; Mizuno, M; Sada, T; Terashima, H | 1 |
| Koike, H | 1 |
| Kato, M; Koike, H; Mizuno, M; Sada, T | 1 |
2 review(s) available for olmesartan medoxomil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
[Carbonyl stress inhibitor towards new therapeutic interventions in diabetic nephropathy].
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus; Diabetic Nephropathies; Glycation End Products, Advanced; Guanidines; Humans; Hydralazine; Hydrazines; Imidazoles; Olmesartan Medoxomil; Oxidative Stress; Pyridoxamine; Tetrazoles | 2004 |
New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist.
Topics: Angiotensin Receptor Antagonists; Animals; Arteriosclerosis; Diabetic Nephropathies; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Olmesartan Medoxomil; Tetrazoles | 2001 |
2 trial(s) available for olmesartan medoxomil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Prospective Studies; Randomized Controlled Trials as Topic; Tetrazoles; Thioctic Acid | 2022 |
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Imidazoles; Kidney; Logistic Models; Male; Middle Aged; Odds Ratio; Olmesartan Medoxomil; Proportional Hazards Models; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome | 2014 |
6 other study(ies) available for olmesartan medoxomil and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Male; Mice; Olmesartan Medoxomil | 2019 |
CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anions; Diabetic Nephropathies; Disease Models, Animal; Imidazoles; Immunohistochemistry; Kidney Glomerulus; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Inbred OLETF; Severity of Illness Index; Tetrazoles; Thiazepines; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2002 |
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glycation End Products, Advanced; Hydralazine; Hypertension, Renal; Imidazoles; Immunohistochemistry; In Vitro Techniques; Kidney; Lipids; Lysine; Male; Olmesartan Medoxomil; Oxidation-Reduction; Proteinuria; Rats; Tetrazoles | 2003 |
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Hydralazine; Imidazoles; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Male; NADPH Oxidases; Olmesartan Medoxomil; Prediabetic State; Rats; Rats, Inbred OLETF; Receptors, Angiotensin; Renin; Tetrazoles; Thiazepines; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta | 2005 |
The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Urea Nitrogen; Body Weight; Chemokine CCL2; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Imidazoles; Immunohistochemistry; Kidney Failure, Chronic; Lipids; Male; Olmesartan Medoxomil; Proteinuria; Rats; Serum Albumin; Survival Rate; Systole; Tetrazoles | 2006 |
Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, Drug; Imidazoles; Insulin; Kidney; Lipids; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Inbred Strains; Rats, Zucker; Receptor, Angiotensin, Type 1; Serum Albumin; Tetrazoles | 2002 |